Crossmark

: The authors state the following conflicts of interest: AA has served as a research investigator, scientific advisor, or speaker to AbbVie, Arcutis, BI, BMS, Leo, UCB, Janssen, Lilly, Novartis, Ortho, Sun, Dermavant, Sanofi, Takeda, Regeneron, and Pfizer. CGB has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Timber, and Palvella; a consultant for AbbVie, Almirall, Amgen, Apogee, Arcutis, Botanix, Connect BioPharma, Dermavant, Eli Lilly, EPI Health/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, Teladoc, Triveni, and UCB. RC has served as an advisor, consultant, speaker, and/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics Inc., Argenx, Astria Therapeutics Inc., Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Galderma, Genentech, GSK, Incyte, Johnson & Johnson, Kenvue, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, UCB, Zai Lab. RC is an Editorial Board member of American Journal of Clinical Dermatology. RC was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. DC has acted as a consultant for, and received honorarium from Cosmetic Ingredient Review (CIR), Dualitas, Ferndale Laboratories, FIDE, Leo, Medimetriks [past], and UCB. He has had stock or stock options in Evommune, Timber [past], and has sat on the Board of Directors for Evommune and Timber [past]. BDE has served as a consultant and/or clinical study investigator for AbbVie, Acelyrin, Allakos, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Bristol-Myers Squibb, Celldex, Concert Pharma, DermBiont, Dermavant Sciences, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, Kymab, LEO Pharma, Navigator Medicines, Novartis, Pfizer, Oruka, Priovant, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma and Ventyx, and as a paid speaker for Bristol-Myers Squibb, Dermavant, Incyte, LEO Pharma, Eli Lilly, Regeneron, Sanofi Genzyme and UCB Pharma. LFE has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB. EGY is an employee of Mount Sinai and has received research grants (paid to the institution) from: Regeneron, Sanofi, Eli Lilly, Galderma, Leo Pharma, Pfizer, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Arcutis, AnaptysBio, Inmagene, Abbvie, Xencor, Q32 Bio, Opsidio, Apollo Therapeutics, Aclaris Therapeutics, Concerto Biosciences. EGY is also a consultant for: Abbvie, Aclaris Therapeutics, Almirall, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Arcutis, Artax Biopharma, Astria, Boerhinger-Ingelhiem, Bristol Meyers Squibb, Celldex, Centrexion Therapeutics, Connect Biopharm, Coty, DBV, Dualitas Therapeutics, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Galderma, Gate Bio, GSK Immunology, Incyte, Inmagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, Leo Pharma, Matchpoint Therapeutics, Merck, Nektar Therapeutics, NUMAB Therapeutics, OTSUKA, Pfizer, Pharmaxis, Proteologix, RAPT, RayThera, Regeneron, Ribon Therapeutics, Sanofi, SATO, Schrödinger, Sitryx, Sun Pharma, Takeda, Teva, TRex Bio, UCB, VRG Therapeutics. JIS has received honoraria as a consultant and/or advisory board member for Abbvie, Aldena, Aldena, Amgen, AObiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, Bodewell, Boehringer-Ingelheim, Bristell-Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Eli Lilly, FIDE, Formation Bio, Galderma, GlaxoSmithKline, Incyte, Inmagene, Invea, Kiniksa, Leo Pharma, Merck, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, TARGET-RWE, Teva, Triveni, UCB, Union, UpToDate; speaker for Abbvie, Arcutis, Dermavant, Eli Lilly, Galderma, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; institution received grants from Galderma, Incyte, Pfizer. ELS reports personal fees from AbbVie, Amgen, Arcutis, Areteia Therapeutics, Astria Therapeutics, Bristol Myers Squibb – BMS, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, Evomunne, FIDE, Forte Bio RX, Galderma, GlaxoSmithKline, Gilead Sciences, Impetus Healthcare, Incyte, Innovaderm Reche, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, LectureLinx (LLX), Leo, Merck, NUMAB Therapeutics AG, Pfizer, Physicians World LLC, PRImE, Recludix Pharma, Regeneron, Roche Products Ltd, Roivant, Sanofi-Genzyme, SITRYX Therapeutics, Trevi therapeutics, Valeant. ELS reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Incyte, Lilly, Kymab, Kyowa Kirin, National Jewish Health, Leo, Pfizer, Regeneron, Sanofi, Target, VeriSkin. WSB reports advisory board fees (paid to institution) from Pfizer, Amgen, Sanofi, research Grants (paid to institution) from Pfizer, and speaker fees (paid to institution) from Arcutis, Galderma. LSG reports investigator, consultant and/or speaker for Abbvie, Amgen, Arcutis,Galderma, Incyte,Leo,Lilly,Pfizer, Regeneron, Sanofi JY has served as a consultant/advisory board/investigator for the following: Abbvie, Arcutis, Astria, Dermavant, iRhythm, Kiehl’s/L’Oreal, Leo, Lilly, National Eczema Association, O’Glacee, Pfizer, Sanofi, Smartpractice, Sol-Gel. He also receives honorarium from UptoDate and BMJ Best Practice.

: All views expressed by the authors are those of the individual and do not represent those of their organization/place of work. Contributors [AA, CB, RC, DC, BE, LE, EG, JS, ES, WSB, LSG, JY] agreed the design of the manuscript and the content. All authors contributed to the development of the manuscript wireframe and subsequent drafts. All authors approved the work before submission, and again after peer review.

: Not applicable.

Document is current

Any future updates will be listed below